<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font18 { font-size : 18; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font29 { font-size : 29; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">the </span>
   <span class="font29">and </span>
   <span class="font18">al., </span>
   <span class="font16">for </span>
   <span class="font15">with </span>
   <span class="font14">that </span>
   <span class="font13">treatment </span>
   <span class="font13">virus </span>
   <span class="font13">against </span>
   <span class="font13">activity </span>
   <span class="font13">antiviral </span>
   <span class="font12">drugs </span>
   <span class="font12">DNA </span>
   <span class="font12">are </span>
   <span class="font12">viral </span>
   <span class="font12">was </span>
   <span class="font12">The </span>
   <span class="font12">drug </span>
   <span class="font12">also </span>
   <span class="font12">approved </span>
   <span class="font12">been </span>
   <span class="font12">has </span>
   <span class="font11">analogue </span>
   <span class="font11">nucleoside </span>
   <span class="font11">combination </span>
   <span class="font11">which </span>
   <span class="font11">{background </span>
   <span class="font11">have </span>
   <span class="font11">its </span>
   <span class="font11">clinical </span>
   <span class="font11">tenofovir </span>
   <span class="font11">used </span>
   <span class="font11">active </span>
   <span class="font11">cancer </span>
   <span class="font11">gemcitabine </span>
   <span class="font11">can </span>
   <span class="font11">HBV </span>
   <span class="font11">HIV </span>
   <span class="font11">HIV- </span>
   <span class="font11">than </span>
   <span class="font11">analogues </span>
   <span class="font11">hepatitis </span>
   <span class="font11">margin </span>
   <span class="font11">infections </span>
   <span class="font11">{border-style </span>
   <span class="font11">into </span>
   <span class="font11">herpes </span>
   <span class="font11">px;} </span>
   <span class="font11">such </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">VZV </span>
   <span class="font11">acyclovir </span>
   <span class="font11">viruses </span>
   <span class="font10">disoproxil </span>
   <span class="font10">inhibits </span>
   <span class="font10">shown </span>
   <span class="font10">this </span>
   <span class="font10">This </span>
   <span class="font10">broad-spectrum </span>
   <span class="font10">human </span>
   <span class="font10">other </span>
   <span class="font10">cell </span>
   <span class="font10">from </span>
   <span class="font10">were </span>
   <span class="font10">cellular </span>
   <span class="font10">inhibitor </span>
   <span class="font10">inhibitors </span>
   <span class="font10">their </span>
   <span class="font10">use </span>
   <span class="font10">Fig. </span>
   <span class="font10">HCV </span>
   <span class="font10">development </span>
   <span class="font10">group </span>
   <span class="font10">nucleos(t)ide-based </span>
   <span class="font10">trials </span>
   <span class="font10">two </span>
   <span class="font10">Agents </span>
   <span class="font10">HSV- </span>
   <span class="font10">RNA </span>
   <span class="font10">antineoplastic </span>
   <span class="font10">infection </span>
   <span class="font10">study </span>
   <span class="font10">Res../j.antiviral... </span>
   <span class="font10">cells </span>
   <span class="font10">chronic </span>
   <span class="font10">effective </span>
   <span class="font10">many </span>
   <span class="font10">most </span>
   <span class="font10">not </span>
   <span class="font10">oral </span>
   <span class="font10">patients </span>
   <span class="font10">therapy </span>
   <span class="font10">thymidine </span>
   <span class="font10">triphosphate </span>
   <span class="font10">(De </span>
   <span class="font10">Gilead </span>
   <span class="font10">after </span>
   <span class="font10">agents </span>
   <span class="font10">both </span>
   <span class="font10">but </span>
   <span class="font10">caused </span>
   <span class="font10">decitabine </span>
   <span class="font10">lamivudine </span>
   <span class="font10">more </span>
   <span class="font10">phase </span>
   <span class="font10">reverse </span>
   <span class="font10">safety </span>
   <span class="font10">some </span>
   <span class="font10">these </span>
   <span class="font10">type </span>
   <span class="font10">vitro </span>
   <span class="font10">(Clouser </span>
   <span class="font10">(e.g., </span>
   <span class="font10">(phase </span>
   <span class="font10">Acyclic </span>
   <span class="font10">FDA </span>
   <span class="font10">HSV </span>
   <span class="font10">HSV, </span>
   <span class="font10">Sciences, </span>
   <span class="font10">Table </span>
   <span class="font10">acyclic </span>
   <span class="font10">acyclovir, </span>
   <span class="font10">antivirals </span>
   <span class="font10">azacytidine </span>
   <span class="font10">chain </span>
   <span class="font10">currently </span>
   <span class="font10">effect </span>
   <span class="font10">efficacy </span>
   <span class="font10">form </span>
   <span class="font10">guanosine </span>
   <span class="font10">herpesviruses </span>
   <span class="font10">may </span>
   <span class="font10">mechanism </span>
   <span class="font10">nucleotide </span>
   <span class="font10">px; </span>
   <span class="font10">review </span>
   <span class="font10">ribonucleotide </span>
   <span class="font10">several </span>
   <span class="font10">zoster </span>
   <span class="font10">{font-family </span>
   <span class="font10">(Beach </span>
   <span class="font10">(Ianevski </span>
   <span class="font10">(NCT). </span>
   <span class="font10">Additionally, </span>
   <span class="font10">Approved </span>
   <span class="font10">Med. </span>
   <span class="font10">Sofosbuvir </span>
   <span class="font10">acid </span>
   <span class="font10">another </span>
   <span class="font10">available </span>
   <span class="font10">based </span>
   <span class="font10">compound </span>
   <span class="font10">could </span>
   <span class="font10">during </span>
   <span class="font10">effects </span>
   <span class="font10">first </span>
   <span class="font10">font-size </span>
   <span class="font10">growth </span>
   <span class="font10">had </span>
   <span class="font10">herpesvirus </span>
   <span class="font10">high </span>
   <span class="font10">infections. </span>
   <span class="font10">inhibition </span>
   <span class="font10">multi-target </span>
   <span class="font10">novel </span>
   <span class="font10">nucleos(t)ide </span>
   <span class="font10">observed </span>
   <span class="font10">phosphorylated </span>
   <span class="font10">polymerase </span>
   <span class="font10">prodrug </span>
   <span class="font10">reported </span>
   <span class="font10">results </span>
   <span class="font10">revealed </span>
   <span class="font10">similar </span>
   <span class="font10">simplex </span>
   <span class="font10">substrate </span>
   <span class="font10">those </span>
   <span class="font10">toxicity </span>
   <span class="font10">valaciclovir </span>
   <span class="font10">(Jordheim </span>
   <span class="font10">(Rawson </span>
   <span class="font10">CMV </span>
   <span class="font10">Chemother../aac.- </span>
   <span class="font10">Clercq, </span>
   <span class="font10">EBV </span>
   <span class="font10">However, </span>
   <span class="font10">Unfortunately, </span>
   <span class="font10">Vidarabine </span>
   <span class="font10">Zika </span>
   <span class="font10">action </span>
   <span class="font10">antibacterial </span>
   <span class="font10">because </span>
   <span class="font10">bioavailability </span>
   <span class="font10">breast </span>
   <span class="font10">compounds </span>
   <span class="font10">concentrations </span>
   <span class="font10">converted </span>
   <span class="font10">cytotoxic </span>
   <span class="font10">double; </span>
   <span class="font10">fever </span>
   <span class="font10">ganciclovir </span>
   <span class="font10">herpesviruses. </span>
   <span class="font10">higher </span>
   <span class="font10">highly </span>
   <span class="font10">inhibit </span>
   <span class="font10">kinase </span>
   <span class="font10">only </span>
   <span class="font10">polymerase. </span>
   <span class="font10">pyrimidine </span>
   <span class="font10">recently </span>
   <span class="font10">replication </span>
   <span class="font10">ribavirin </span>
   <span class="font10">show </span>
   <span class="font10">showed </span>
   <span class="font10">significant </span>
   <span class="font10">sofosbuvir </span>
   <span class="font10">studies </span>
   <span class="font10">synergistic </span>
   <span class="font10">synthesis </span>
   <span class="font10">through </span>
   <span class="font10">trial </span>
   <span class="font10">(Kang </span>
   <span class="font10">(emtricitabine </span>
   <span class="font10">)HIV- </span>
   <span class="font10">-azacytidine </span>
   <span class="font10">Acyclovir </span>
   <span class="font10">Another </span>
   <span class="font10">Chem. </span>
   <span class="font10">Elsevier </span>
   <span class="font10">FLUAV </span>
   <span class="font10">Gemcitabine </span>
   <span class="font10">Lamivudine </span>
   <span class="font10">Nucleoside </span>
   <span class="font10">Tenofovir </span>
   <span class="font10">These </span>
   <span class="font10">VZV, </span>
   <span class="font10">ViiV </span>
   <span class="font10">Zhou, </span>
   <span class="font10">acute </span>
   <span class="font10">adenosine </span>
   <span class="font10">advanced </span>
   <span class="font10">agent </span>
   <span class="font10">alafenamide </span>
   <span class="font10">animal </span>
   <span class="font10">anticancer </span>
   <span class="font10">antimetabolites </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">cases </span>
   <span class="font10">cause </span>
   <span class="font10">cells. </span>
   <span class="font10">comparison </span>
   <span class="font10">developed </span>
   <span class="font10">different </span>
   <span class="font10">drug, </span>
   <span class="font10">enzymes </span>
   <span class="font10">famciclovir </span>
   <span class="font10">idoxuridine </span>
   <span class="font10">immune </span>
   <span class="font10">including </span>
   <span class="font10">infected </span>
   <span class="font10">leukaemia </span>
   <span class="font10">low </span>
   <span class="font10">metastatic </span>
   <span class="font10">million </span>
   <span class="font10">much </span>
   <span class="font10">multiple </span>
   <span class="font10">mutagenesis </span>
   <span class="font10">number </span>
   <span class="font10">one </span>
   <span class="font10">pancreatic </span>
   <span class="font10">penciclovir </span>
   <span class="font10">potent </span>
   <span class="font10">range </span>
   <span class="font10">reductase </span>
   <span class="font10">research </span>
   <span class="font10">selective </span>
   <span class="font10">significantly </span>
   <span class="font10">solid; </span>
   <span class="font10">strains </span>
   <span class="font10">syndrome </span>
   <span class="font10">synergy </span>
   <span class="font10">transcriptase </span>
   <span class="font10">treat </span>
   <span class="font10">types </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(Alexeeva </span>
   <span class="font10">(Littler </span>
   <span class="font10">(NCT) </span>
   <span class="font10">(lamivudine </span>
   <span class="font10">According </span>
   <span class="font10">AdV </span>
   <span class="font10">COVID- </span>
   <span class="font10">Clofarabine </span>
   <span class="font10">Currently, </span>
   <span class="font10">Gemzar </span>
   <span class="font10">HHV- </span>
   <span class="font10">HIV, </span>
   <span class="font10">HSV-, </span>
   <span class="font10">Health </span>
   <span class="font10">Healthcare, </span>
   <span class="font10">Lamont, </span>
   <span class="font10">Moreover, </span>
   <span class="font10">Mylan </span>
   <span class="font10">Opin. </span>
   <span class="font10">Pharmaceuticals, </span>
   <span class="font10">Recently, </span>
   <span class="font10">Res. </span>
   <span class="font10">Several </span>
   <span class="font10">Trifluridine </span>
   <span class="font10">United </span>
   <span class="font10">Virol../jvi.- </span>
   <span class="font10">ZIKV </span>
   <span class="font10">absorbed </span>
   <span class="font10">act </span>
   <span class="font10">activities </span>
   <span class="font10">administration </span>
   <span class="font10">agent. </span>
   <span class="font10">amino </span>
   <span class="font10">and/or </span>
   <span class="font10">anti-HIV </span>
   <span class="font10">antimetabolite </span>
   <span class="font10">applied </span>
   <span class="font10">being </span>
   <span class="font10">better </span>
   <span class="font10">bladder </span>
   <span class="font10">bold </span>
   <span class="font10">brivudine </span>
   <span class="font10">cancer. </span>
   <span class="font10">candidates </span>
   <span class="font10">causes </span>
   <span class="font10">centre </span>
   <span class="font10">colorectal </span>
   <span class="font10">commonly </span>
   <span class="font10">courier; </span>
   <span class="font10">cytidine </span>
   <span class="font10">data </span>
   <span class="font10">demonstrated </span>
   <span class="font10">described </span>
   <span class="font10">diseases </span>
   <span class="font10">drug-resistant </span>
   <span class="font10">due </span>
   <span class="font10">em; </span>
   <span class="font10">emtricitabine </span>
   <span class="font10">enzyme </span>
   <span class="font10">ester </span>
   <span class="font10">even </span>
   <span class="font10">exhibit </span>
   <span class="font10">found </span>
   <span class="font10">immunodeficiency </span>
   <span class="font10">important </span>
   <span class="font10">include </span>
   <span class="font10">incorporated </span>
   <span class="font10">increase </span>
   <span class="font10">increased </span>
   <span class="font10">less </span>
   <span class="font10">metabolite </span>
   <span class="font10">natural </span>
   <span class="font10">new </span>
   <span class="font10">non-nucleoside </span>
   <span class="font10">over </span>
   <span class="font10">polymerases </span>
   <span class="font10">preclinical </span>
   <span class="font10">prodrugs </span>
   <span class="font10">pt;} </span>
   <span class="font10">rate </span>
   <span class="font10">reduced </span>
   <span class="font10">reduction </span>
   <span class="font10">related </span>
   <span class="font10">replaced </span>
   <span class="font10">resource </span>
   <span class="font10">ring </span>
   <span class="font10">strategies </span>
   <span class="font10">tested </span>
   <span class="font10">they </span>
   <span class="font10">towards </span>
   <span class="font10">transcription </span>
   <span class="font10">transporters </span>
   <span class="font10">treatments </span>
   <span class="font10">using </span>
   <span class="font10">valaciclovir, </span>
   <span class="font10">vidarabine </span>
   <span class="font10">well </span>
   <span class="font10">while </span>
   <span class="font10">wide </span>
  </p>
 </body>
</html>
